| abstract |
Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions comprising the compounds. Methods of use of the Btk inhibitors, alone or in combination with other therapeutic agents, are described for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer (including lymphoma), and inflammatory diseases or symptoms. |